Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03367767 · ClinicalTrials.gov registry record

Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On

A clinical trial, sponsored by National Eye Institute (NEI).

Completed
Registry status
709
Enrollment target

NCT03367767: Completed study, sponsored by National Eye Institute (NEI).

NCT03367767 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 709 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03367767 has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
709 participants
Enrollment target

Study Summary

Background: Age-related macular degeneration (AMD) and cataracts are two eye diseases. They were studied in the Age-Related Eye Disease Study (AREDS2) and the AREDS2 Follow-On study. These studies followed the natural course of the diseases. They also provided data on the long-term effects of certain oral supplements on AMD. Objective: To study the long-term effects of oral supplements on several things. These include incidences of lung cancer, development of late AMD, cataract surgery, cognitive function, and cardiovascular events. Eligibility: Former AREDS2 and AREDS2 Follow-On participants Design: Participants will have 1 visit. It will include: An eye exam that tests how well participants can see, measures eye pressure, and checks eye movements. The pupil will be dilated with eye drops. Pictures will be taken of the retina and the inside of the eye. Participants will grip a device in their hand to measure their grip strength. A blood sample will be taken. This will be stored for future genetic research. Cells may be created from the sample. A small sample of skin will be taken. Sponsoring Institution: National Eye Institute

Trial Details

FieldValue
Enrollment Target 709 participants
Start Date 2018-05-23
Est. Completion 2019-03-21
National Eye Institute (NEI)

221 total trials

What the finished NCT03367767 record still lists

NCT03367767 is an observational study that tracks outcomes without assigning an intervention. The registered 709 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT03367767 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03367767 about?

NCT03367767 is a clinical study titled "Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On". Background: Age-related macular degeneration (AMD) and cataracts are two eye diseases. They were studied in the Age-Related Eye Disease Study (AREDS2) and the AREDS2 Follow-On study. These studies followed the natural course of the diseases. They also provided data on the long-term effects of certa...

What is the current status of trial NCT03367767?

This trial is currently completed. The enrollment target is 709 participants. The study started on 2018-05-23. Estimated completion is 2019-03-21.

Who is sponsoring clinical trial NCT03367767?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06179160 · 710 participants · Phase 1

    A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  • NCT06235697 · 710 participants · Phase 3

    Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

  • NCT06470867 · 710 participants · NA

    Randomized Controlled Effectiveness Trial of VA S.A.V.E.

  • NCT07022483 · 710 participants · Phase 3

    Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03367767, the US trial registry maintained by the National Library of Medicine. NCT03367767 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.